What’s more, this is definitely not another finding. Androgen treatment has been utilized to treat PMS for more than 60 maxulin apotek.
Legend #9: It might expand the danger of bosom disease
It was perceived however right on time as 1937 that bosom disease seemed to be an estrogen delicate malignancy and that testosterone went about as an offset to estrogen. Clinical preliminaries in primates and people have affirmed that testosterone beneficially affects bosom tissue by diminishing bosom multiplication and keeping incitement from estradiol.
Notwithstanding, some epidemiological investigations have detailed a relationship between raised androgens and bosom malignant growth. Be that as it may, these examinations experience the ill effects of methodological constraints, and all the more significantly, don’t represent related raised estradiol levels and expanded weight file. Furthermore, the circumstances and logical results understanding of these investigations clashes with the known organic impact of testosterone.
Despite the fact that testosterone is bosom defensive, it can aromatize to estradiol and have an auxiliary, stimulatory impact on the estrogen receptor. Be that as it may, when testosterone is joined with an aromatase inhibitor in a subcutaneous embed, it blocks testosterone from aromatizing.
This type of therapy has been displayed to successfully treat androgen insufficiency side effects in bosom disease survivors and is as of now being assessed in a U.S. public malignancy study. Furthermore, Dimitrakakis and Glaser see a diminished frequency of bosom disease in ladies treated with testosterone or testosterone with anastrozole inserts.
Fantasy #10: The security of testosterone use in ladies has not been set up
Testosterone inserts have been utilized securely in ladies since 1938. Any genuine concerns would be grounded at this point.
Long haul information exists on the effective and safe utilization of testosterone in dosages of up to 225 mg in as long as 40 years of treatment. Also, long haul follow up investigations on supra-pharmacologic dosages used to ‘female to male’ transsexual patients report no increment in mortality, bosom malignant growth, vascular sickness or other significant medical issues.